CE, MOC & Certificates

Designed for clinicians, scientists, and all other members of the cancer care and research community, this three-day meeting focuses on clinical and translational advances in immuno-oncology. Expert faculty offer new insights on the application of immunotherapy in melanoma, lung cancer, genitourinary cancers, head and neck cancer, and hematologic malignancies. Faculty will also discuss considerations for clinical trial designs, the treatment of microsatellite instability high solid tumors, and emerging targets in immunotherapy. Abstract presentations will be featured in Oral Abstract Sessions and Poster Sessions.

Accreditation and Designation Statement

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Society of Clinical Oncology designates this live activity for AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA/NCCPA Credit Designation Statement – PAs

PAs may claim Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

ANCC Credit Designation Statement - Nurses

Contact hours are awarded for this activity.

All non-physician attendees are welcome to submit a request for a Certificate of Participation, which may enable non-physicians to apply their meeting participation toward re-licensure. Please note, however, that all final decisions regarding certificate acceptance will be made by the licensing organization to which the certificate is submitted.

Target Audience

This Symposium is designed for physicians and researchers involved in multidisciplinary clinical cancer care including, but not limited to medical, surgical, and radiation oncologists; pathologists; radiologists; and other translational-oriented laboratory scientists; nurses, pharmacists, advanced practice providers, and other health care professionals involved in clinical cancer care and cancer research in immuno-oncology.

Educational Needs Statement

The Symposium provides a clinical focus on the use of immunotherapy to treat patients with cancer.  Even as research efforts continue to swell in this area, there have also been a number of new immunotherapy-related approvals of both agents and diagnostics over the past year.  This has created a clear educational need for oncology professionals who are facing an increasing complexity in selecting and interpreting diagnostic tests, making treatment decisions, and managing the effects of those treatments. 

Learning Objectives

Upon participation in this activity, attendees will be able to

  • Demonstrate competence in describing principles and the use of cellular therapy in treating patients with cancer;
  • Outline the effective use of genomics data to inform both treatment selection and potential immune response;
  • Compare and contrast effectiveness in the treatment of patients with cancer in different disease sites, and how these experiences have informed clinical research and potentially led to drug approvals that are not tissue specific;

Disclaimer and Unlabeled Usage Statement

The information presented is that of the contributing faculty and presenters and does not necessarily represent the views of the Symposium Cosponsors and/or any named company or organization providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty or presenters. Therefore, before presenting any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.